RBC Bioscience Corporation (TPEX:6848)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
20.60
+0.90 (4.57%)
Jun 12, 2026, 1:50 PM CST
Market Cap281.19M +21.4%
Revenue (ttm)219.71M +7.0%
Net Income23.54M +9.2%
EPS1.64 +9.3%
Shares Out 14.27M
PE Ratio12.01
Forward PEn/a
Dividend1.50 (7.61%)
Ex-Dividend DateOct 2, 2025
Volume77,438
Open19.85
Previous Close19.70
Day's Range19.70 - 21.40
52-Week Range14.30 - 20.75
Beta0.42
Analystsn/a
Price Targetn/a
Earnings DateAug 11, 2026

About RBC Bioscience

RBC Bioscience Corporation manufactures and sells reagents and devices for life science and molecular diagnosis Taiwan. It offers MagCore Plus II Automated Nucleic Acid Extractor, a robotic bench-top workstation for nucleic acid purification; MagCore Super Automated Nucleic Acid Extractor, an automated workstation for nucleic acid extraction; and MagCore® EDA Automatic Extraction and Smart PCR Setup, an instrument for nucleic acid extraction and PCR setup pre-treatment. The company also provides NGS, genomic DNA, viral nucleic acids, and total ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1995
Employees 50
Stock Exchange Taipei Exchange
Ticker Symbol 6848
Full Company Profile

Financial Performance

In 2025, RBC Bioscience's revenue was 219.71 million, an increase of 7.05% compared to the previous year's 205.25 million. Earnings were 23.54 million, an increase of 9.17%.

Financial Statements